OKYO Pharma Reports Phase 2 Trial Shows Urcosimod Improves Corneal Nerve Health in Neuropathic Corneal Pain
I'm PortAI, I can summarize articles.
OKYO Pharma Ltd. announced positive results from its Phase 2 trial of urcosimod for neuropathic corneal pain. The study showed that patients treated with 0.05% urcosimod experienced improvements in corneal nerve fiber count and length, unlike the placebo group. These findings suggest urcosimod may positively impact corneal nerve structure in NCP patients. The original content was published by OKYO Pharma via GlobeNewswire on December 11, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments